-
-
-
-
-
-
-
Neurocrine presents INGREZZA data for tardive dyskinesia patients
-
-
-
-
-
-
-
Neurocrine publishes expert guidelines for glucocorticoid reduction with CRENESSITY
-
-
-
-
-
-
-
INGREZZA shows higher treatment persistence than AUSTEDO XR in study
-
-
-
-
-
-
-
Baird on Neurocrine Bio's Soleno deal: Incrementally positive on acquisition
-
-
-
-
-
-
-
RBC Capital: 'We see upside in multiple scenarios, and so would remain buyers'
-
-
-
-
-
-
-
Neurocrine presents data showing INGREZZA achieved higher target occupancy
-
-
-
-
-
-
-
TD Cowen on Neurocrine Bio. (NBIX): 'R&D Day Highlights Uniquely Diversified And Robust Early Pipeline'
-
427,074 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

